• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Insights & Articles
    • The Clinical Landscape: Strategic Insights into Retinal Care
      • The Modern Clinical Retina Landscape: A Strategic Overview
      • Surgical Approaches to Retinal Detachment: A Comparative Analysis
      • Gene Therapy in Retina: A Commercial and Clinical Appraisal
      • Evolving Treatment Paradigms for Diabetic Macular Edema
      • Analysis of the Anti-VEGF Market: From Revolution to Refinement
      • A Patient’s Guide to Understanding Age-Related Macular Degeneration (AMD)
    • The Business of Retina: Mastering Operations and Financial Health
      • Anatomy of a Retina Practice: A Strategic Guide to Financial Health and Operations
      • The Impact of Private Equity: Reshaping the Business of Retina
      • The Complete 2025 Guide to Ophthalmic J-Codes & Reimbursement
      • The Buy-and-Bill Model: A High-Risk, High-Reward Strategy
      • Staffing for Success: Key Roles in a High-Volume Retina Practice
      • Key Technology Investments for an Efficient Retina Clinic
      • Decoding CMS Reimbursement: A Guide to J-Codes and Revenue Cycle Management
    • The Innovation Pipeline: Shaping the Future of Retinal Care
      • Beyond the Needle: The Future of Drug Delivery in Retina
      • Heads-Up vs. Traditional: A Comparison of Surgical Visualization Platforms
      • How AI is Changing the Game in Retinal Disease Screening
      • The Rise of At-Home Monitoring for AMD
    • The Professional Ecosystem: Building a Career in Retina
      • A Day in the Life of a Retina Specialist: A Day of Preserving Sight
      • Industry vs. Academia: Choosing Your Career Path in Retina
      • The Role of Key Opinion Leaders (KOLs) in Retina
      • Maximizing Your ASRS Experience: A Fellow’s Guide
      • Navigating the Retina World: A Guide to Key Societies, Conferences, and Career Paths
  • Services
    • Search Engine Optimization (SEO) & Reputation Management
    • Content Marketing & Optometrist Network Development
    • Specialized Recruitment & Staffing Support
    • Professional Branding & Key Opinion Leader (KOL) Development
    • On-Demand Patient Education & Marketing Materials
    • Market Intelligence & M&A Consulting
  • Contact Us
    • Events
    • Subscribe
    • Submissions
Retina Consultant

Retina Consultant

Visionary News & Insightful Strategy

Retina Roundup Advertisement

A Patient’s Guide to Understanding Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration, or AMD, is a primary cause of vision loss for Americans over the age of 50. The disease attacks the macula, which is the part of your eye’s retina responsible for sharp, straight-ahead vision. While it doesn’t cause complete blindness, losing your central vision can make it difficult to read, drive, or recognize the faces of loved ones.

This guide, based on information from the National Eye Institute and the Centers for Disease Control and Prevention, will walk you through what AMD is and what you can do about it.

The Two Types of AMD: Dry and Wet

It is essential to understand that AMD comes in two distinct forms.

Dry AMD (Atrophic)

The “dry” form is the most common type of AMD. It is a slow-moving condition where the light-sensitive cells in the macula gradually break down. According to the National Eye Institute (NEI), a key sign of dry AMD is the presence of small yellow deposits called drusen. As the condition progresses over many years, central vision slowly becomes more blurry.

Wet AMD (Neovascular)

The “wet” form is less common but much more serious. It can cause faster and more severe vision loss. Wet AMD happens when abnormal blood vessels start to grow underneath the retina. These new vessels are fragile and leak blood and fluid, which can scar the macula. This is a more urgent condition that requires prompt medical attention.

Symptoms: What to Look For

According to the Centers for Disease Control and Prevention (CDC), you may not have any symptoms in the early stages. However, as the disease gets worse, you might notice:

  • Blurry distance or reading vision.
  • Dark, blurry areas in the center of your vision.
  • Straight lines, like a doorframe, appearing wavy or crooked.

Risk Factors You Can Control

While age and family history are major risk factors, there are several you can manage:

  • Smoking: The CDC notes that smoking is a major risk factor. Quitting smoking is one of the best things you can do for your eye health.
  • Diet and Exercise: Maintaining a healthy weight and eating a diet rich in leafy greens can help.
  • Blood Pressure: Managing your blood pressure is also important for your overall and eye health.

Diagnosis and Modern Treatment

An eye doctor can diagnose AMD with a comprehensive dilated eye exam. If they suspect wet AMD, they may use advanced imaging to look for leaking blood vessels.

While there is no cure for AMD, treatments can slow the disease and prevent severe vision loss.

  • For Dry AMD: The NEI’s landmark Age-Related Eye Disease Studies (AREDS/AREDS2) found that a specific formula of vitamins and minerals can slow down the disease for some people with intermediate to late-stage AMD.
  • For Wet AMD: The standard treatment is injections of anti-VEGF drugs into the eye. These drugs stop the abnormal blood vessels from growing and leaking, and can prevent further vision loss.

If you are over 50, regular eye exams are the best way to catch AMD early. If you notice any changes in your vision, see your eye doctor right away.

Works Cited

  1. National Eye Institute. (2023). Age-Related Macular Degeneration. Retrieved July 2, 2025, from https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration.
  2. Centers for Disease Control and Prevention. (2022). Don’t Lose Sight of Macular Degeneration. Retrieved July 2, 2025, from https://www.cdc.gov/visionhealth/resources/features/macular-degeneration.html.

Enjoying this article? The future of retina is in sight. Subscribe to our weekly “Retina Roundup.”

Please enable JavaScript in your browser to complete this form.
Loading

Primary Sidebar

More to See

Uveitis and Corticosteroid or Immunosuppressive Use Are Risk Factors for Postsurgical Endophthalmitis

February 6, 2026 By AAO News Feed

Opioid use for corneal cross-linking: Potential concerns and drug stewardship

February 6, 2026 By Healio Ophthalmology

Pegcetacoplan slows GA progression with no change in vision loss

February 6, 2026 By Healio Ophthalmology

CDC carries on without a permanent director

February 6, 2026 By Healio Ophthalmology

ACA enrollment plummeted in 2026

February 6, 2026 By Healio Ophthalmology

Healio Community webinar offers tips for best AI utilization

February 6, 2026 By Healio Ophthalmology

Simultaneous Segmentation of Geographic Atrophy in Longitudinally Acquired Fundus Autofluorescence Images

February 5, 2026 By Ophthalmology Science

Prevalence and Risk Factors for Keratoconus in Young Adults Assessed with Tomography and Corneal Biomechanics: A Prospective Cross-Sectional Study

February 5, 2026 By Ophthalmology Science

Persistent vision loss of eyes lost to follow-up with diabetic macular edema receiving intravitreal anti-vascular endothelial growth factor therapy

February 5, 2026 By Ophthalmology Science

Week in Review: Easing Nighttime IOP by Lowering Pillow Height, Metformin May Reduce Later-Stage AMD Risk

February 5, 2026 By AAO News Feed

Footer

A RETINA-SPECIFIC ORGANIZATION

It’s clearly an advantage to work with a consulting group that’s focused on your industry. The team at Retina Consultant has over 50 years of retina-specific experience in healthcare business, practice management, marketing & operations.

We’ve got our eyes on working with the best retina groups and vendors in the industry.

See the best;  get in touch.

Recent News Posts

  • Factors Associated with Machine Learning-Based Predictions of Retinal Aging using Teleretinal Screening Images from Patients with Diabetes
  • Uveitis and Corticosteroid or Immunosuppressive Use Are Risk Factors for Postsurgical Endophthalmitis
  • Opioid use for corneal cross-linking: Potential concerns and drug stewardship
  • Pegcetacoplan slows GA progression with no change in vision loss
  • CDC carries on without a permanent director

Search

Retina Consultant
Copyright © 2026